Voyager Therapeutics Provides Fourth Quarter and Full Year 2015 Investor Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Wedbush Remains Bullish on Voyager Therapeutics (VYGR) Following 4Q Financials
March 18, 2016 8:29 AM EDTWedbush reiterated an Outperform rating and $36.00 price target on Voyager Therapeutics (NASDAQ: VYGR) following 4Q financial results.
Analyst David Nierengarten commented, "VYGR reported net income of ($8.8M), below our estimate of ($6.1M) in part due to GAAP expenses of $1.5M related to pre-IPO... More
Voyager Therapeutics (VYGR) Misses Q4 EPS by 12c
March 17, 2016 8:25 AM EDTVoyager Therapeutics (NASDAQ: VYGR) reported Q4 EPS of ($0.67), $0.12 worse than the analyst estimate of ($0.55). Revenue for the quarter came in at $4.94 million versus the consensus estimate of $3.73 million.
Cash, cash equivalents and marketable securities as of December 31, 2015 were approximately $224 million, compared to $161 million on September... More
